Citations

Clear

9383 citation(s) found for "Thomas, PS".

The Hidden Power of Humility: Elevating Patient and Provider Experience Through Clinician Self-Awareness and Patient-Centered Care
Rizzo, Marco, Hunderfund, Andrea Leep, Pestorious, Ann, Welch, Thomas J, Rizzo, Marco , Hunderfund, Andrea N. Leep , Welch, Thomas

Mayo Clinic

Journal of Patient Experience | January 20, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/23743735261415652 | PMID 41573242 Get It

Humility is one of the most powerful and sometimes least understood virtues we can possess. It is often misinterpreted as a sign of weakness, especially today, where self-promotion is encouraged and celebrated. Many people view humility as “thinking less of ourselves.” In truth, humility is not thinking less of oneself; rather it is appropriately thinking less about oneself. Our ability as caregivers in putting the needs of the patient at the center of all we do is enhanced through our humility. A steady focus on the needs of the patient helps us gain an honest assessment of both our strengths and limitations. Studies have shown that patient outcomes and experiences are strongly associated with provider humility. This article aims to shine a light on the power of humility and its impact on patient experience, psychological and cultural safety, and the provider-patient relationship.
Abstract B079: Persist: a molecular signature for prostate cancer patients with preexisting treatment-persistent cells associated with aggressive disease
Ballesio, Francesco , Taavitsainen, Sinja , Alshalalfa, Mohammed , Kiviaho, Antti , Ismail, Mazlina , Nätkin, Reetta , Giesen, Alexander, Munro, Thomas, Proudfoot, James A., Davicioni, Elai, Cooperberg, Matthew, Karnes, R. Jeffrey., Jiang, Ruochen, Joniau, Steven, Attard, Gerhardt, Nykter, Matti , Joniau, Steven , Joniau, Steven , Proudfoot, James A. , Ryu, Hyunnam Monica , Davicioni, Elai , Cooperberg, Matthew R , Karnes, R. Jeffrey , Jiang, Ruochen, Attard, Gerhardt , Claessens, Frank , Urbanucci, Alfonso

Mayo Clinic

Cancer Research | January 20, 2026 | Volume: 86 | Issue: 2_Supplement | Pages: B079-B079

10.1158/1538-7445.prostateca26-b079 Get It

Abstract Background Prostate cancer is a heterogeneous disease comprising diverse cell types within the tumor microenvironment that support cancer cell survival. Using single cell and spatial transcriptomics, we previously identified subpopulations of treatment-persistent cancer cells exhibiting regenerative properties and a distinct molecular signature. Herein, we aimed to characterize the locked ‘Persist’ signature (PS) and its association with outcomes in a large cohort of non-metastatic prostate cancer tumors. Methods Patients with non-metastatic prostate cancer that underwent Decipher prostate genomic classifier and whole-transcriptome profiling on biopsy (BX, n=146,941) and radical prostatectomy (RP, n=55,329) specimens between October 2016 and February 2024 were included (Veracyte Inc., San Diego, CA, USA). Baseline clinical and pathological data from deidentified patients as well as signature scores were retrieved from the Decipher Genomic Resource for Intelligent Discovery (GRID) registry (Clinical Trials identifier: NCT02609269). The PS score based on the expression of 17 genes was calculated for all samples. Results PS was significantly associated with adverse clinical and pathological variables. In biopsy sample, PS was higher in cases with worse T3/4 clinical stage, Grade group (GG4-5), and high/very high NCCN risk (p<0.001 for all). In RP sample, PS was significantly higher in patients with GG4-5, extraprostatic extension, seminal vesicle invasion and lymph node involvement (p<0.001 for all). PS was also higher in patients with very high Decipher (>0.85) in both BX and RP (p<0.001 for both). When evaluating the prognosis of PS in multiple retrospective cohorts, PS in biopsy was prognostic of adverse pathology features at RP. PS was also prognostic of distance metastasis (DM) in multiple RP cohorts with long-term follow up (META855). In the ARNEO trial testing apalutamide in addition to ADT as neo-adjuvant treatment prior RP, PS was prognostic of early recurrence. In the Stampede trial, PS was prognostic of progression free survival, PCSM and OS in both non-metastatic and metastatic disease. When associating PS with other GRID signatures, PS was higher in samples with homologous recombination deficiency, TP53 mutations, Luminal B and luminal proliferating subtypes. On the other hand, PS was lower in samples with low androgen receptor-activity, RB-loss and neuroendocrine-like tumors. Finally, PS was positively correlated with radiation sensitivity signatures. Conclusions Persist is a novel molecular signature associated with more aggressive tumor characteristics. Future studies aim to further examine beyond this signature potential to identify patients at risk of aggressive prostate cancer, and understand what the optimal treatments for those with treatment-persistent prostate cancer cells are. Citation Format: Francesco Ballesio, Sinja Taavitsainen, Mohammed Alshalalfa, Antti Kiviaho, Mazlina Ismail, Reetta Nätkin, Alexander Giesen, Thomas Munro, James A. Proudfoot, Hyunnam Ryu, Elai Davicioni, Matthew C. Cooperberg, R. Jeffrey. Karnes, Ruochen Jiang, Steven Joniau, Gerhardt Attard, Frank Claessens, Matti Nykter, Alfonso Urbanucci. Persist: a molecular signature for prostate cancer patients with preexisting treatment-persistent cells associated with aggressive disease [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Prostate Cancer Research and Treatment; 2026 Jan 20-22; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86(2_Suppl):Abstract nr B079.
Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection
Ghazal, Rachad , Wang, Min, Cao, Jenny Jia Ling, Vyas, Hridyanshu , Liu, Duan , Nair, Asha , Wang, Li , Yip, D., Patel, Parag C., Steidley, D. Eric , Hardaway, Brian , Clavell, Alfredo L., Kushwaha, Sudhir S. , Eisen, Howard J., Pereira, Naveen, Srinivas, Akshatha N. , Steidley, David E, Hardaway, Brian W, Pereira, Naveen L , Liu, Duan , Ghazal, Rachad , Srinivas, Akshatha N., Smith, Byron H. , Yip, Daniel , Patel, Parag C. , Clavell, Alfredo L. , Park, Walter D. , Stegall, Mark D. , Eisen, Howard J.

Mayo Clinic

Transplantation Direct | January 20, 2026 | Volume: 12 | Issue: 2 | Pages: e1882

10.1097/txd.0000000000001882 | PMID 41567756 Get It

Background. Acute cellular rejection (ACR) remains a major cause of morbidity after heart transplantation despite advances in immunosuppression. Whole genome transcriptomic profiling offers a systems-based, unbiased approach to elucidate the molecular mechanisms underlying ACR. However, noninvasive, longitudinal biomarker assessments capable of capturing the temporal dynamics of rejection biology remain scarce. Methods. RNA sequencing of peripheral blood from heart transplant recipients before, during, and after ACR was compared with nonrejection controls. Pathway analysis was conducted using differentially expressed genes (DEGs), and a machine learning approach was applied to assess gene-based prediction of ACR. Results. A total of 235 rejection-specific significant DEGs and 863 postrejection DEGs (false discovery rate < 0.05) were identified. During ACR, DEGs were enriched for T-cell activation/differentiation, apoptosis, and B-cell receptor signaling pathways. By combining the 2 sets of DEGs, a panel of 71 common genes was identified that reflected the significant, longitudinal transcriptomic dynamics of ACR. In an elastic net machine learning–based classifier, DYNLL1 and SERF2 were identified as ACR predictive genes, and achieved a cross-validated area under the receiver operating characteristic curve of 0.63. Conclusions. Peripheral blood transcriptomics identify dynamic temporal responses in ACR including T- and B-cell pathways with potential ACR predictive genes that warrant further investigation.
Conventional versus advanced imaging selection for endovascular treatment of basilar artery occlusion strokes
Chen, Huanwen , Colasurdo, Marco, Matsukawa, Hidetoshi, Cunningham, Conor, Maier, Ilko , Kasab, Sami Al, Jabbour, Pascal , Kim, Joon-Tae, Wolfe, Stacey Quintero, Rai, Ansaar, Starke, Robert M, Psychogios, Marios-Nikos, Goyal, Nitin, Yoshimura, Shinichi, Cuellar, Hugo, Grossberg, Jonathan A, Alawieh, Ali, Alaraj, Ali, Ezzeldin, Mohamad, Romano, Daniele G, Tanweer, Omar, Mascitelli, Justin, Fragata, Isabel, Polifka, Adam, Siddiqui, Fazeel, Osbun, Joshua, Crosa, Roberto, Matouk, Charles, Park, Min S, Levitt, Michael R, Brinjikji, Waleed, Moss, Mark, Dumont, Travis, Daglioglu, Ergun, Williamson, Richard, Navia, Pedro, Leacy, Reade De, Chowdhry, Shakeel, Altschul, David J, Spiotta, Alejandro M, Kan, Peter, Wolfe, Stacey Q , Alaraj, Ali , Altschul, David , Samaniego, Edgar A , Jabbour, Pascal , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Chen, Huanwen , Colasurdo, Marco, Matsukawa, Hidetoshi, Cunningham, Conor, Kasab, Sami Al, Kim, Joon-Tae, Wolfe, Stacey Quintero, Rai, Ansaar, Starke, Robert M, Psychogios, Marios‐Nikos , Goyal, Nitin, Yoshimura, Shinichi, Cuellar, Hugo, Grossberg, Jonathan A, Alawieh, Ali, Ezzeldin, Mohamad, Romano, Daniele G, Tanweer, Omar, Mascitelli, Justin, Fragata, Isabel, Polifka, Adam, Siddiqui, Fazeel, Osbun, Joshua, Crosa, Roberto, Matouk, Charles, Park, Min S, Levitt, Michael R, Brinjikji, Waleed, Moss, Mark, Dumont, Travis, Daglioglu, Ergun, Williamson, Richard, Navia, Pedro, Leacy, Reade De, Chowdhry, Shakeel, Spiotta, Alejandro M, Kan, Peter

Mayo Clinic

European Stroke Journal | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1093/esj/23969873251364973 | PMID 41614473 Get It

Abstract Introduction Endovascular thrombectomy (EVT) is an effective treatment for basilar artery occlusion (BAO) stroke in select patients. While there is a growing body of literature suggesting that advanced imaging modalities such as computed tomography perfusion (CTP) and magnetic resonance (MR) may not be necessary for selecting anterior circulation large vessel occlusion stroke patients for EVT, whether advanced imaging may be superior to conventional imaging (non-contrast CT and CT angiography) in identifying good treatment candidates among BAO patients is less clear. Patients and methods This was a multicenter retrospective cohort study of BAO EVT patients treated from 2013 to 2022 in the Stroke Thrombectomy and Aneurysm Registry. Patients selected for EVT by advanced imaging (CTP or MR) were matched with those selected by conventional imaging using propensity score matching (PSM) accounting for possible confounders. Primary outcome was functional independence at 90 days. Other outcomes include bedridden state or death at 90-days and symptomatic intracranial hemorrhage (sICH). Results 268 patients were included. 150 patients were selected for BAO EVT by conventional imaging, 86 by CTP, and 32 by MR. Patients selected by advanced imaging were significantly older than those selected by conventional imaging (median age 71 vs 64 years, p = 0.001); patient characteristics were otherwise similar between cohorts. After PSM, 90-day outcomes were similar between the two cohorts (p = 0.56), with similar rates of functional independence (39.4% vs 35.1%, p = 0.65), bedridden state or death (40.4% vs 44.7%, p = 0.66), and sICH (3.3% vs 5.7%, p = 0.49) for conventional and advanced imaging groups, respectively. Results were similar across treatment time windows (all p &gt; 0.05). Conclusions Selecting patients for basilar EVT using conventional versus advanced imaging did not result in different clinical outcomes, regardless of treatment time windows. Conventional imaging appears sufficient as a first-line tool for selecting basilar EVT patients in routine clinical practice.
Frontline aspiration versus stent retriever thrombectomy for M2 occlusions: Insights from the STAR registry
Gaub, Michael , Kasem, Rahim Abo , Maier, Ilko , Rai, Ansaar, Jabbour, Pascal, Kim, Joon-Tae, Wolfe, Stacey Q , Starke, Robert M, Psychogios, Marios-Nikos, Goyal, Nitin, Dye, Justin , Alaraj, Ali, Ezzeldin, Mohamad , Yoshimura, Shinichi, Fiorella, David, Tanweer, Omar, Romano, Daniele G, Navia, Pedro, Cuellar, Hugo H, Polifka, Adam , Osbun, Joshua, Siddiqui, Fazeel , Moss, Mark, Mokin, Maxim, Matouk, Charles, Park, Min S, Brinjikji, Waleed, Dağlıoğlu, Ergün , Williamson, Richard, Altschul, D, Ogilvy, Christopher S, Levitt, Michael R, Gory, Benjamin, Paul, A, Kan, Peter, Casagrande, Walter, Chowdhry, Shakeel, Stiefel, Michael , Grandhi, Ramesh, Spiotta, Alejandro M , Mascitelli, Justin, Jabbour, Pascal , Ogilvy, Christopher S. , Alaraj, Ali , Altschul, David , Abo Kasem, Rahim , Jabbour, Pascal , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Ogilvy, Christopher S , Rai, Ansaar , Kim, Joon‐Tae , Howard, Brian M , Alawieh, Ali , Psychogios, Marios‐Nikos , Shaban, Amir , Fiorella, David , Tanweer, Omar , Romano, Daniele Giuseppe , Navía, Pedro , Fragata, Isabel , Osbun, Joshua W , Moss, Mark, Limaye, Kaustubh , Mokin, Maxim , Matouk, Charles , Brinjikji, Waleed , Williamson, Richard, Crosa, Roberto , Levitt, Michael R. , Gory, Benjamin , Paul, Alexandra R , Chowdhry, Shakeel , Grandhi, Ramesh , Mascitelli, Justin R

Mayo Clinic

European Stroke Journal | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1093/esj/23969873251381924 | PMID 41614461 Get It

Abstract Background Recent trials have furthered uncertainty regarding the endovascular benefit for medium vessel occlusions (MeVO). Stent retrievers (SR) were employed in the first attempt in most interventional arm participants. We sought to compare outcomes in acute MCA M2 occlusions between frontline aspiration and SR, and to delineate procedural and anatomical covariates associated with differential treatment effect. Methods Retrospective analysis of a multicenter stroke thrombectomy cohort identified cases of MT for M2 occlusions. Unmatched and propensity score-matched (PSM) cohorts were generated comparing frontline aspiration to standalone and combined SR. The primary outcome was functional independence (mRS 0–2) at 90 days. Recanalization, symptomatic intracranial hemorrhage (sICH), mortality, and the effect of M2 laterality, division occlusion and procedure time were assessed. Results About 1734 patients with M2 occlusions underwent either frontline aspiration (n = 711) or SR/combined (n = 958) thrombectomy between 2013 and 2024. PSM analysis favored aspiration for functional independence (49.9% vs 44.0%, OR 1.27 (1.03–1.57)), complete recanalization (61.2% vs 48.7%, OR 1.66 (1.34–2.05)), complete first pass effect (35.0% vs 27.6%, OR 1.42 (1.13–1.78)), and sICH (3.5% vs 6.2%, OR 0.55 (0.33–0.91)), with no difference in mortality. Frontline aspiration had significantly shorter procedural times (median 28 [IQR 15–49.5] vs 51 [IQR 35–78] minutes; p &lt; 0.001). For every minute increase in procedure time, the probability of functional independence decreased significantly (p &lt; 0.001) less with frontline aspiration (0.35%) compared to SR/combined (1.61%). Conclusion Frontline aspiration for M2 occlusions resulted in better clinical and angiographic outcomes compared to SRs. Future trials for MeVO with a focus on contact aspiration thrombectomy may succeed where recent trials have failed.
GRADE Guidance: Update on Developing Good Practice Statements in Guidelines
Dewidar, Omar , Akl, Elie A, Saz-Parkinson, Zuleika, Langendam, Miranda , Meerpohl, Joerg J , Marti, Melanie, Djulbegović, Benjamin , Brignardello-Petersen, Romina, Chu, Derek, Murad, M Hassan, Canelo-Aybar, C., Alonso-Coello, Pablo, Qaseem, Amir, Schwingshackl, Lukas , Klugar, Miloslav , Comas, David Rigau, Iorio, Alfonso , Turgeon, A. F., Shamliyan, Tatyana A, Munn, Zachary, Mathioudakis, Alexander G., Piggott, Thomas , Lotfi, Tamara, Guyatt, Gordon, Schünemann, Holger J, Akl, Elie A. , Schünemann, Holger J. , Chu, Derek K. , Akl, Elie A , Saz-Parkinson, Zuleika , Langendam, Miranda W , Meerpohl, Joerg J , Marti, Melanie , Mayer, Martin , Djulbegovic, Benjamin , Brignardello-Petersen, Romina , Chu, Derek K , Canelo-Aybar, Carlos , Mathew, Joseph L , Alonso-Coello, Pablo , Qaseem, Amir , Schwingshackl, Lukas , Bognanni, Antonio , Morgan, Rebecca L , Klugar, Miloslav , Iorio, Alfonso , Turgeon, Alexis F , Munn, Zachary , Mathioudakis, Alexander G , Piggott, Thomas , Lotfi, Tamara , Pottie, Kevin , Schünemann, Holger J , Morgano, Gian Paolo , Parmelli, Elena , Brignardello‐Petersen, Romina , Murad, M Hassan , Alonso‐Coello, Pablo , Rojas, María Ximena , Morgan, Rebecca L. , Stallings, Elena , Tugwell, Peter , Darzi, Andrea J. , Shamliyan, Tatyana , Lotfi, Tamara , Pottie, Kevin

Mayo Clinic

Annals of Internal Medicine | January 19, 2026 | Volume: 179 | Issue: 3 | Pages: 430-439

10.7326/annals-25-00431 | PMID 41554128 Get It

Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease
Pentchev, Julian V., Jackson, Trever, Khan, Naazneen , Rosewood, Thea , Huang, Yen‐Ning, Nho, Kwangslk, Saykin, Andrew J., Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Riddle, Meghan, Salloway, Steven, Atri, Alireza, Honig, Lawrence S., Johnson, Erik C. B., Turner, Raymond Scott, Masdeu, Joseph C. , Foroud, Tatiana M., Clark, David, Hammers, Dustin B., Dage, Jeffrey L., Kirby, Kala, Ghetti, Bernardino, Newell, Kathy, Onyike, Chiadi U., Day, Gregory S., Graff‐Radford, Neill R., Murray, Melissa E., Jones, D. Richard, Jack, Clifford R., Vemuri, Prashanthi, Touroutoglou, Alexandra, Duara, Ranjan, Grant, Ian, Sha, Sharon, Wingo, Thomas S., Beckett, Laurel A., Rogalski, Emily J, Mendez, Mario F., Kramer, Joel, Joie, Renaud La, Grinberg, Lea T., Koeppe, Robert, Wolk, David A., Aisen, Paul, RAMAN, REMA , Toga, Arthur, Kukull, Walter A., Musiek, Erik, Womack, Kyle, Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Apostolova, Liana G., Nudelman, Kelly N. H., Murray, Melissa E. , Carrillo, María C. , Turner, Raymond Scott , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , Murray, Melissa E , La Joie, Renaud , Rabinovici, Gil D , Huang, Yen‐Ning, Nho, Kwangsik T. , Saykin, Andrew J. , Eloyan, Ani , Taurone, Alexander, Riddle, Meghan , Salloway, Steve , Atri, Alireza , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Foroud, Tatiana , Clark, David, Hammers, Dustin B , Dage, Jeffrey L. , Ghetti, Bernardino , Newell, Kathy L. , Onyike, Chiadi U. , Graff‐Radford, Neill R. , Jones, David T. , Jack, Clifford R. , Vemuri, Prashanthi , Touroutoglou, Alexandra , Duara, Ranjan , Sha, Sharon J. , Beckett, Laurel , Rogalskı, Emily , Mendez, Mario F. , Kramer, Joel, Blazhenets, Ganna , Grinberg, Lea T. , Koeppe, Robert A. , Wolk, David A. , Aisen, Paul , Toga, Arthur W. , Kukull, Walter A. , Musiek, Erik , Dickerson, Bradford Clark , Apostolova, Liana G. , Nudelman, Kelly

Mayo Clinic

Alzheimer's & Dementia | January 14, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71066 | PMID 41532810 Get It

Abstract INTRODUCTION The genetic basis of sporadic early‐onset Alzheimer's disease (EOAD) remains largely unknown, prompting evaluation of late‐onset Alzheimer's disease (LOAD) polygenic risk in EOAD. METHODS A LOAD polygenic score (PGS) was calculated in the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) study and tested for associations with AD risk, cognitive performance, and imaging and fluid biomarkers. RESULTS Though PGS was elevated in LOAD and EOAD, it was not a significant predictor of EOAD adjusting for APOE ε4 carrier status and was not associated with age of EOAD onset ( p = 0.106) or with cognitive performance ( p = 0.417). In LEADS, greater LOAD PGS was associated with differences in neuroimaging and fluid biomarkers, including elevated synaptosomal‐associated protein 25 (SNAP‐25) ( p = 2.3 × 10 −5 ). DISCUSSION While LOAD polygenic risk contributed minimally to EOAD onset and cognitive dysfunction, PGS association with fluid biomarkers in LEADS suggests a role for LOAD polygenic risk in EOAD pathophysiology. Highlights LOAD PGSs were elevated in both LOAD and EOAD compared to controls; however, LOAD PGS did not significantly predict EOAD risk, age at onset, or cognitive performance independent of APOE ε4 in the LEADS. Higher LOAD PGS was associated with lower amyloid PET Centiloids (less brain amyloid deposition) as well as lower CSF biomarker Aβ42 in LEADS (proxy marker suggesting higher brain amyloid deposition) in LEADS; these contradictory findings support the need for larger studies to further investigate whether LOAD PGS is associated with increased amyloid deposition in EOAD. Higher LOAD PGS was also associated with higher levels of CSF synaptosomal‐associated protein 25 (SNAP‐25), a key component of the SNARE complex, suggesting that LOAD genetic factors may contribute to dysregulation of synaptic transmission and/or pathological protein aggregation in EOAD.
Associated Risks to the Treatment of Unruptured Intracranial Aneurysms (MARTA) Score: Development and External Validation
Diana, Francesco , Siddiqui, Adnan H., Tomasello, Alejandro , Hernández, David , Requena, Manuel, Lascuevas, Marta de Dios , Xu, Bin, Liao, Yujun, Raz, Eytan, Nossek, Erez , Stroh-Holly, Nico , Gmeiner, Matthias , Civelli, Vittorio , Arpaia, Francesco , Khattar, Nicolas, Nickele, Christopher M., Arthur, Adam S., Charbel, Fady T. , Vajkoczy, Peter, Sanchin, Amina, Jabbour, Pascal, Lanzino, Giuseppe, Raabe, Andreas, Velinov, N., Burkhardt, Jan Karl, Saei, Hamzah, Salcuni, Andrea , Manfrini, Elia , Romoli, Michele, Siddiqui, Adnan H. , Vajkoczy, Peter , Ransom, Ryan C, Romoli, Michele , Siddiqui, Adnan H , Jaikumar, Vinay , Baig, Ammad A. , Requena, Manuel , Arikán, Fuat , Liao, Yujun , Raz, Eytan , Chung, Charlotte , Hoffman, Haydn , Nickele, Christopher, Arthur, Adam Stephen , Jabbour, Pascal , Lanzino, Giuseppe , Ransom, Ryan C. , Raabe, Andreas , Petutschnigg, Thomas , Hassan, Ameer E , Saei, Hamzah, Eusebi, Paolo , Bonura, Adriano , Peschillo, Simone

Mayo Clinic

Neurosurgery | January 14, 2026 | Volume: 99 | Issue: 3 | Pages: 603-614

10.1227/neu.0000000000003900 | PMID 41532751 Get It

BACKGROUND AND OBJECTIVES: Unruptured intracranial aneurysms (UIAs) are increasingly detected and require careful management to prevent rupture. No externally validated score currently predicts procedural risk to guide treatment decisions. We developed and validated 2 predictive scores for complications after endovascular treatment (EVT) or neurosurgical treatment (NT) of UIA using routinely collected clinical and aneurysmal features. METHODS: We conducted a multicenter retrospective study including patients with UIA treated with EVT or NT across 15 neurovascular centers (2014-2024). Predictive models were built using multivariable logistic regression, with variables derived from Delphi consensus. The primary outcome was a composite safety end point: new neurological deficits, modified Rankin Scale (mRS) worsening (≥1 point or mRS 2-5 within 30 days), or procedural death. Internal validation used bootstrapping, and external validation was performed temporally and institutionally. Model performance was assessed using area under the receiver operating characteristic curve (AUROC) and calibration. Final scores, named Morbidity and Mortality Associated Risk in the Treatment of UIAs (MARTA)-EVT and MARTA-NT, were compared with existing models identified through systematic review. RESULTS: Among 2647 patients (1907 EVT and 740 NT), procedural complications occurred in 6.3% (EVT) and 12.8% (NT). Independent predictors included age, baseline mRS, aneurysm location, size, morphology, and procedural factors. MARTA-EVT (AUROC = 0.68, 95% CI = 0.57-0.78) and MARTA-NT (AUROC = 0.65, 95% CI = 0.54-0.77) showed moderate discrimination and good calibration. MARTA-EVT outperformed existing models; MARTA-NT performed similarly to SAFETEA. Predictive models are available open-source: https://martascoreapp.shinyapps.io/martascoreapp/. CONCLUSION: MARTA-EVT and MARTA-NT are validated tools for predicting procedural risks in UIA treatment and may support patient counseling and clinical decision making.
Validation of 13 102 International Classification of Diseases, Tenth Revision, Clinical Modification codes using a large language model-based system
Wang, Yichen , Song, Yilin , Siu, Rex K. , Nimma, Induja R., Savage, Thomas , Wang, Yiming, Li, Zhichen, Ramai, Daryl, Wang, J., Badurdeen, Dilhana, Tao, Cui, Kumbhari, Vivek , Huang, Yuting, Siu, Rex, Huang, Yuting , Wang, Yichen , Yan, Yan , Tao, Cui

Mayo Clinic

Journal of the American Medical Informatics Association | January 14, 2026 | Volume: 33 | Issue: 5 | Pages: 947-956

10.1093/jamia/ocag008 | PMID 41670956 Get It

Abstract Objectives To comprehensively evaluate the validity of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes for both prevalent diagnoses and less common diseases, and to assess the performance of a large language model (LLM)-based system in validating these codes. Materials and Methods This retrospective study analyzed hospital admissions from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. We developed a validated LLM-based system using GPT-4o, refined through iterative prompt engineering, to assess ICD-10-CM code validity. We measured the positive predictive value (PPV) of ICD-10-CM codes, PPV of principal and secondary diagnoses, and the performance of an LLM-based system in code validation. Results Among 865 079 assigned codes, the PPV was 84.6% (95% CI, 84.5%-84.6%). Principal diagnoses had a PPV of 93.9% (95% CI, 93.7%-94.1%), while secondary diagnoses had a PPV of 83.8% (95% CI, 83.7%-83.9%). The LLM system demonstrated high performance in validating ICD codes, achieving 93.6% accuracy, 95.4% sensitivity, and 85.2% specificity. Among correctly assigned secondary diagnoses, the majority (67.9%) represented historical or baseline conditions, while 32.1% reflected active conditions that deviated from baseline status; 22.3% of these emerged after hospital admission. PPV decreases with later diagnosis positions, with the largest decline occurring between principal and secondary diagnoses. Discussion and Conclusion In this large-scale evaluation, ICD-10-CM codes exhibited generally high accuracy, though variability existed by position and condition type. A validated LLM system performed comparably to physician review and offers a scalable means to improve coding accuracy. These findings support the potential for integrating LLM-based auditing into routine workflows to strengthen the quality of administrative and research data.